BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25152991)

  • 1. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
    Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
    Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.
    Donato MF; Fabrizi F; Fogazzi GB; Cresseri D; Passerini P; Martin P; Messa P
    Int J Artif Organs; 2013 Jan; 36(1):63-8. PubMed ID: 23280083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
    Mak SK; Sin HK; Lo KY; Lo MW; Chan SF; Lo KC; Wong YY; Ho LY; Wong PN; Wong AKM
    Clin Exp Nephrol; 2017 Oct; 21(5):764-770. PubMed ID: 28083764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
    Zhao XY; Rakhda MI; Wang TI; Jia JD
    Transplant Proc; 2013 Mar; 45(2):824-7. PubMed ID: 23498828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
    Buti M; Gros B; Oyagüez I; Andrade RJ; Serra MA; Turnes J; Casado MA
    Farm Hosp; 2014 Sep; 38(5):418-29. PubMed ID: 25344136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Autoimmune hepatitis and membranous glomerulonephritis under immune therapy in chronic hepatitis C].
    Paparoupa M; Huy Ho NA; Schuppert F
    Dtsch Med Wochenschr; 2016 May; 141(10):709-11. PubMed ID: 27176065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
    Lee MY; Cho H; Kim YM; Lee JS
    Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
    Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
    ; Coco B; Caraceni P; Aghemo A; Bitetto D; Bruno R; Ciancio A; Marzioni M; Petta S; Rendina M; Valenti L;
    Dig Liver Dis; 2014 Jan; 46(1):18-24. PubMed ID: 24119482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
    Nair S; Waters B
    Exp Clin Transplant; 2014 Apr; 12(2):117-22. PubMed ID: 24702143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
    Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
    [No Abstract]   [Full Text] [Related]  

  • 15. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
    Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].
    Nishimura T
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():193-8. PubMed ID: 26845929
    [No Abstract]   [Full Text] [Related]  

  • 17. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
    Virolés Torrent S; López Nuñez C; Hombrados Verde M; Figa Francesch M; Ferri Iglesias MJ; Louvriex Freire R; Acero Fernández D
    Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of recurrent hepatitis C virus after liver transplantation.
    Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
    World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
    Zeuzem S
    J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
    [No Abstract]   [Full Text] [Related]  

  • 20. Occurrence of diffuse, poorly differentiated hepatocellular carcinoma during pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.
    Capanni M; Lorefice E; Benini MC; Biagini MR; Tozzi A; Salvadori E; Colagrande S; Surrenti C; Milani S
    J Chemother; 2008 Jun; 20(3):380-4. PubMed ID: 18606596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.